Reported July 2, 2026: Orthofix Medical Says Medicare Will Restore Pre-May 18 Reimbursement Rates For Bone Growth Stimulators After CMS Reve
On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for Medicare & Medicaid Services ("CMS") modified certain billing requirements and Medicare fee schedule treatmen